Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

24.10 -0.08 (-0.33%)
Streaming Delayed Price Updated: 10:17 AM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes Plc

< Previous 1 2 3 4 5 6 7 8 9 Next >
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
The Analyst Landscape: 7 Takes On Alkermes
Via Benzinga
In a market where value is scarce, NASDAQ:ALKS offers a refreshing opportunity with its solid fundamentals.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
Investors should take a close look at these biotech stocks as they position themselves to provide high returns. 
Via InvestorPlace
6 Analysts Assess Alkermes: What You Need To Know
Via Benzinga
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
7 Analysts Assess Alkermes: What You Need To Know
Via Benzinga
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
Should you consider ALKERMES PLC (NASDAQ:ALKS) for growth investing? 
Via Chartmill
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Breaking Down Alkermes: 5 Analysts Share Their Views
Via Benzinga
ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024
ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2... 
Via Benzinga
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Is NASDAQ:ALKS suited for growth investing?
Is ALKERMES PLC (NASDAQ:ALKS) suited for growth investing? 
Via Chartmill
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
Via Benzinga
Exploring NASDAQ:ALKS's growth characteristics.
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Alkermes's Earnings Outlook
Via Benzinga
Is NASDAQ:ALKS suited for growth investing?
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential. 
Via InvestorPlace
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday. 
Via Investor's Business Daily
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.